PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22270929-11	2012	The improvement in DFS with docetaxel-containing regimens was observed across all subgroups (age, under or over 50; number of involved nodes; hormone receptor or HER2 status (including triple negative status), or administration schedule (sequential or concomitant).	Docetaxel	28-37	nuclear receptor subfamily 4 group A member 1	Homo sapiens	142-158	
19741502-8	2009	HER2-negative, HR-positive ABC patients have a relatively good prognostic after docetaxel-containing first-line therapy.	Docetaxel	80-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	15-17	
20198292-11	2009	Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.	Docetaxel	46-55	nuclear receptor subfamily 4 group A member 1	Homo sapiens	126-142	
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Docetaxel	187-196	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104	
33408886-0	2020	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy.	Docetaxel	83-92	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-56	
34150608-12	2021	Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy.	Docetaxel	226-235	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-158	
23831020-0	2013	Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells.	Docetaxel	53-62	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19	
23450278-1	2013	BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer.	Docetaxel	75-84	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-238